anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To obtain a propolis extract excellent in stability and aroma which can easily develop its effect by controlling pH to a specified value to improve the solubility of the effective component of propolis in water. SOLUTION: Propolis is brought into contact with an aq. soln. of a hydrophilic org. solvent without controlling pH to dissolve and extract the effective component of the propolis. Then the soln. is controlled to pH5.5 to 7.0. with a pH controlling agent to obtain the extract. Or, propolis is brought into contact with an aq. soln. of a hydrophilic org. solvent the pH of which is controlled to &gt;=5.5, preferably between &gt;=5.5 and about &lt;8.0 with a pH controlling agent, so as to dissolve and extract the effective component. If necessary, the soln. is controlled to pH5.5 to 7.0 with a pH controlling agent to obtain the extract. By this method, the effect of propolis can easily be obtd. and the obtd. propolis extract shows excellent stability and good aroma.  Thereby, it is unnecessary to limit the use of a propolis extract only in a stimulative hydrophilic org. solvent soln. having high concn. which is conventionally used, but the obtd. propolis can be used in a low irritation soln. having low concn.
The invention describes novel nitrosated and/or nitrosylated nebivolol, novel nitrosated and/or nitrosylated metabolites of nebivolol and novel compositions comprising at least one nitrosated and/or nitrosylated nebivolol and/or at least one nitrosated and/or nitrosylated metabolite of nebivolol, and optionally, at least one nitric oxide donor and/or at least one antioxidant or a pharmaceutically acceptable salt thereof, and/or at least one compound used to treat cardiovascular disease or a pharmaceutically acceptable salt thereof, and/or at least one nitrosated compound used to treat cardiovascular diseases. The invention also provides novel compositions comprising nebivolol and/or at least one metabolite of nebivolol and at least one nitric oxide donor, and, optionally, at least one antioxidant or a pharmaceutically acceptable salt thereof, and/or at least one compound used to treat cardiovascular diseases or a pharmaceutically acceptable salt thereof, and/or at least one nitrosated compound used to treat cardiovascular diseases. The compounds and compositions of the invention can also be bound to a matrix. The nitric oxide donor is a compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and may preferably be isosorbide dinitrate and/or isosorbide mononitrate. The antioxidant may preferably be a hydralazine compound or a pharmaceutically acceptable salt thereof. The invention also provides methods for treating and/or preventing vascular diseases characterized by nitric oxide insufficiency; and for treating and/or preventing Raynaud&#39;s syndrome; and for treating and/or preventing cardiovascular diseases or disorders.
PURPOSE:To obtain a promoter for hepatic regeneration capable of increasing hepatic cells and promoting the regeneration of the liver. CONSTITUTION:The objective promoter for hepatic regeneration comprises alanine and/or glutamine in an effective amount as an essential ingredient. When a mixture of the alanine with the glutamine is used, the weight ratio thereof is preferably (1/0.1) to (1/10). In this case, they may be contained as a di- to a tripeptide. The daily dose for an adult is &gt;=1g in the total amount of the amino acids. In order to ensure promoting effects on the hepatic regeneration, this promoter is preferably continuously administered at an interval of, e.g. 3hr or 6hr. Furthermore, since the amino acids are respectively approved as foods, there is no possibility of exhibiting toxicity, especially acute toxicity. The promoter for the hepatic regeneration has the effects and remarkable amelioration of hepatopathy can be expected, wide utilization such as a therapeutic agent for fulminant hepatitis, an ameliorant for viral hepatopathy, a therapeutic agent or a preventing agent for hepatopathy due to medicines such as anticancer agents or promotion of hepatic regeneration after the operation of the liver such as liver transplantation, induction of renal regeneration, etc.
NEW MATERIAL:A compound shown by the formula I or its salt. USE:An antibacterial agent. Having improved antibacterial activity against a wide range of bacteria, showing improved activity especially against Gram-positive bacteria. A dose is 250-3,000mg daily per adult, and administered 1-4 times daily. PREPARATION:A substituted oxyiminothiazolylacetic acid derivative shown by the formula II (R&lt;1&gt; and R&lt;2&gt; are H, or amino-protecting group) or its reactive derivative is reacted with a 7-amino-3-cephem derivative shown by the formula IIIin a solvent such as dioxane, tetrahydrofuran, etc. under cooling - at room temperature. The reaction product is optionally deprotected to give a compound shown by the formula I .
The present invention provides a conjugate of haemoglobin and human seralbumin and a preparation method thereof. The hemoglobin is purified by using membrane filtration and ion exchange chromatography. A liquid phase one-step coupling method, a two-step coupling method or a coupling method capable of absorbing protein on a solid phase medium is used for couple the hemoglobin and a human serum albumin. The coupled product is treated by ion exchange chromatography, ultrafiltration and gel filtration chromatography purification. The molecular weight of the prepared coupled product is from 100 to 300KD. The coupled product is the conjugate of 1 to 3 haemoglobins which are already intramolecularly linked or not intramolecularly linked and 1 to 3 persons&#39; serum albumin molecules. A solid phase adsorption method is used for obtaining the conjugate with the ratio of the haemoglobin to the human serum albumin of 1:1. The final product has the good characteristics of blood substitutes.
PURPOSE:To produce a liq. detergent and a dentifrice excellent in washing power and polishing power and having substantially a transparent appearance on a visual sense. CONSTITUTION:In an inorg. powder having low refractive index and the liq. detergent and the dentifrice using this powder as an abrasive material, this inorg. powder having low refractive index of &lt;=1.40 in an aqueous medium is composed of porous particles consisting essentially of SiO2 or SiO2 and Al2O3 and having 1-50mum average grain size in which fine pores having substantially &lt;=100nm diameter occupies 8-80vol.% of the vol. of each particle, and the fine pores are blocked off at the vicinity of the particle surface and a communication with the outside is interrupted.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a new heme oxygenase-1-inducing substance free from NO release action which was one of problems of present HO-1-inducing substance and having long duration and to provide a method for producing the culture medium, a method for producing a preserving solution for organs for transportation and a method for producing an experimental animal by using the heme oxygenase-1-inducing substance.  &lt;P&gt;SOLUTION: The heme oxygenase-1-inducing agent comprises one or more kinds of a polyamine derivative, its hydrochloride and the other pharmaceutically acceptable salt as active ingredients. As the polyamine derivative, e.g. spermine or spermidine can be used. The method for producing the preserving solution for organs for transplantation comprises adding the heme oxygenase-1-inducing substance to the preserving solution for organs for transportation. The method for producing the experimental animals comprises administering the heme oxygenase-1-inducing agent to the experimental animal so as to induce a state highly developing the heme oxygenase.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
PURPOSE:To obtain the subject cosmetic having excellent transparency and feeling and giving excellent make-up by using a liquid oil for cosmetic, an oil-gelatinizing agent for the solidification of the liquid oil and a specific fine pigment powder derived from a water-soluble dye and an insolubilizing agent for the dye, as active components. CONSTITUTION:The objective cosmetic contains, as active components, (A) a liquid oil for cosmetic, (B) an oil-gelatinizing agent capable of solidifying the component A and (C) a fine pigment powder having an average particle diameter of &lt;=0.1mum and produced by reacting a water-soluble dye with an insolubilizing agent for the dye in a W/O emulsion. The component A is e.g. avocado oil, liquid paraffin, etc., or their mixture and its amount is 50-99wt.%, preferably 70-95wt.% based on the cosmetic. The component B is e.g. 12- hydroxystearic acid and its amount is preferably 0.1-30wt.%. The component C is e.g. a combination of an acid dye and a basic polyaluminum salt.
A dermatological treatment and composition therefor are described for periodic and effective maintenance of a skin peel patient&#39;s subsequent skin condition. The treatment does not use radiation, can be performed quickly, is readily controlled by visual observation of the applied composition, and is self-limiting. The method includes forming a composition having a visualizing agent, a surfactant and an acid or acid equivalent dispersed in a carrier liquid, the concentration of the last not exceeding 30 %; applying the composition to a predetermined area of the patient&#39;s skin in a quantity effective to result in a predetermined degree of mild exfoliation of the skin; determining degree of coverage of the area of skin by visual observation of extent of the visualizing agent; and maintaining the composition in contact with the area of skin for a period of time effective to result in the predetermined degree of exfoliation of the skin. Compositions of this type are also disclosed. Preferably, the acid or acid equivalent will be trichloroacetic acid and the surfactant will be a saponin or complex of saponins, preferably steroid saponins. The concentrations of the three principal ingredients, the amount of the composition used and the length of time of the application and treatment will vary according to the specific depth of peel or degree of maintenance which the dermatologist believes appropriate for a particular patient.
PURPOSE: To obtain products which are less decreased in lactic acid bacteria in spite of room-temp. storage by culturing milk products contg. the lactic acid bacteria in an inert gaseous atmosphere and freeze drying these products in production of dry products consisting essentially of cow&#39;s milk or milk products and contg. the lactic acid bacteria. CONSTITUTION: The dry products are produced by adding the lactic acid bacteria (Bifiodobacteria) to a mixture consisting essentially of the cow&#39;s milk or milk products and carbide, culturing the bacteria in the inert gaseous atmosphere of nitrogen, etc., molding the mixture to flow molding to form into disk, chip, rod and other shapes and freeze drying them in the inert gaseous atmosphere. The products are airtightly and aroma-tightly packed and are storable at room temp.
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain a percutaneous administration composition containing a piroxicam-inorganic substance complex and a patch system using the same.  &lt;P&gt;SOLUTION: The percutaneous administration composition containing a piroxicam-inorganic substance complex has improved piroxicam solubility and stability and prevents recrystallization. The patch system of piroxicam percutaneous administration uses the same. The piroxicam percutaneous administration composition comprises 0.1-25 mass% of piroxicam-inorganic substance complex in which piroxicam is intercalated into between layers of expansive clay, 50-80 mass% of adhesive polymer substance and 0.1-25 mass% of absorption promoter. The piroxicam percutaneous administration patch system uses the same. Since piroxicam is dispersed into between layers of clay substance at a molecular level and exists, the piroxicam-inorganic substance complex has excellent dispersibility, stability and solubility of piroxicam, prevents recrystallization and exhibits excellent absorption and skin permeability. Accordingly, the piroxicam-inorganic substance complex exhibits excellent antiinflammation and analgesic effect with a small amount and prevents an adverse effect.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
The invention relates to siRNA for inhibiting caspase-3 gene expression. The sequence thereof is as follows: the sense strand: 5&#39;-GAGTCTGACTGGAAAGCCGAA-3&#39;and the anti-sense strand: 5&#39;-TTCGGCTTTCCAGGAAGACTC-3&#39;. When entering nerve cells, the siRNA can obviously improve the vitality of nerve cells, obviously reduce the expression of apoptosis-related genes, i.e. caspase-3, of the nerve cells, lower the apoptosis and necrosis rate of the nerve cells and obviously reduce the expression of Alzheimer marker protein APP and that of Tau protein. The siRNA is capable of efficiently and specifically inhibiting the expression of disease-related gene caspase-3 so as to cause the silencing of relevant disease genes, and carrying out effective knockout on the expression of target genes to achieve the therapeutic purpose. The invention can be used for preparing medicines for inhibiting the apoptosis of the nerve cells or curing neurodegenerative diseases.
PROBLEM TO BE SOLVED: To obtain an additive for preparations, capable of being utilized as a diluent of effective components in the fields of food, medicament, feed, or the like, having various uses and hardly reacting with the effective components. SOLUTION: This additive for preparations is used in a composition including no effective component having a primary amine and comprises trehalose. The additive is readily soluble in water, becomes a colorless and transparent aqueous solution having low viscosity, has slight sweetness and is excellent in a dose feeling. The powder of the additive is excellent in miscibility, granulating property, compressive moldability and shows a good fluidity. The additive is pharmaceutically stable, hardly reacts with effective components and doesn&#39;t cause drug interaction. Since the additive has the above advantages, it is useful as fillers for solid preparations, diluents for liquid preparations, or the like.
A family of proteins, including a specific human protein designated as HIP1, has been identified that interact differently with the gene product of a normal (16 CAG repeat) and an expanded (44 CAG repeat) HD gene. Expression of the HIP1 protein was found to be enriched in the brain. Analysis of the sequence of the HIP1 protein indicated that it includes a death effector domain (DED), suggesting an apoptotic function. Thus, it appears that a normal function of Huntingtin may be to bind HIP1 and related apoptosis modulators, reducing its effectiveness in stimulating cell death. Since expanded huntingtin performs this function less well, there is an increase in HIP1-modulated cell death in individuals with an expanded repeat in the HD gene.  This understanding of the likely role of huntingtin and HIP1 or related proteins (collectively &#34;HIP-apoptosis modulating proteins&#34;) in the pathology of Huntington&#39;s disease offers several possibilities for therapy. First, because the function of huntingtin apparently depends at least in part on the ability to interact with HIP-apoptosis modulating proteins, added expression (e.g., via gene therapy) of normal (non-expanded) huntingtin or of the HIP-binding region of huntingtin should provide a therapeutic benefit. Other DED-interacting peptides could also be used to mask and reduce the interaction of HIP-apoptosis modulating proteins with the death signaling complex.  Alternatively, a mutant form of HIP-protein from which the DED has been deleted might be introduced, for example using gene therapy techniques.  Because HIP-apoptosis modulating proteins have been shown to self-associate, a protein with a deleted DED may compete with endogenous HIP-protein in the formation of these associations, thereby reducing the amount of apoptotically-active HIP-protein.
The tablet comprises a carrier material and, contained in the carrier material, at least one active substance, especially a foodstuff, a pharmaceutical or chemical product, plant seed or animal semen, and the carrier material (8) is in the form of an absorbent fabric which is composed of nonwoven filaments and contains a binder which swells on uptake of water, and which on swelling of the binder spontaneously breaks down into a filament pulp. The active substance (2) can be injected, e.g. with a micrometering pump, in the form of a solution, dispersion or melt into the fabric or be applied or impressed onto the latter. The carrier material is preferably composed of a fabric of nonwoven cellulose filaments whose filaments are held together in the dry state by a hydrophilic gel, e.g. by gelatin or bone glue. The fabric can be provided with a pore-closing water- soluble or water-permeable coating which expediently has a water- repellant surface. The tablet form is particularly distinguished by economic and low-cost manufacture. &lt;IMAGE&gt;
The invention discloses the grape dashing enzyme ramification dealing with the blood platelet assembling and the thrombin active ability and the producing process belonging to the domain of the gene engineering and the producing art of the biology dissolving bolt medicament. The nucleotide acid serial of the grape dashing enzyme ramification restraining the blood platelet assembling and the thrombin active ability is disclosed. The producing process fuses the RGD series, the C end series of the hirudin and the constructed low antigen and high active ability SAK breaking body gene using the gene recombining technology outer the body, at the same time, the Xa gene incising location point and the flexible connecting arm and it&#39;s C end amino acid is decorated, the another amino acid is appended. The fusing albumen expressing carrier is constructed to gain the efficient expressed recombining SAK ramification using the double enzyme chipping and the PCR appraising alkalescence of the constructed breaking body. The ramification has the function of restraining the blood platelet assembling and interdicting the thrombin active ability and establishes the base of developing the new generation dissolving bolt medication. So the applied range of the new SAK ramification is expanded largely.
&lt;P&gt;PROBLEM TO BE SOLVED: To clarify structures of modified low-density lipoprotein receptor of vascular endothelial cell, and to provide a DNA sequence encoding the modified low-density lipoprotein receptor of vascular endothelial cell.  &lt;P&gt;SOLUTION: There is provided a DNA sequence substantially composed of a region encoding the receptor of the modified low-density lipoprotein of specific mammalian vascular endothelial cells. The DNA sequence may be a cDNA clone originating from an open reading frame of the modified low-density lipoprotein receptor gene of natural mammalian vascular endothelial cells. The DNA sequence may be a DNA sequence hybridizing with the cDNA clone, and encoding the modified low-density lipoprotein receptor of mammalian vascular endothelial cells having biological activity. The DNA sequence described above may be a DNA sequence encoding the modified low-density lipoprotein receptor as the result of a degeneration of the genetic code.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
FIELD: medicine. ^ SUBSTANCE: invention concerns feeding of cats and dogs. A weight-reduction composition contains tyrosine in amount not exceeding approximately 0.4 wt %, particularly in amount approximately 0.08 to approximately 0.38 wt % and preferentially approximately 0.2 to approximately 0.36 wt % on solids. Method of animal&#39;s weight reduction implies that it is considered whether an animal requires weight reduction and feeding an animal with overweight with feed containing a composition with low content of tyrosine. Method of decreasing food consumption provides feeding of an animal with overweight with feed containing said composition. The feed additive, additional food or delicacy for weight reduction in dogs and the cats contain tyrosine in amount less than 0.4 wt % on solids. ^ EFFECT: invention allows reducing weight in domestic animals with overweight or obesity. ^ 24 cl, 4 dwg, 5 tbl
Novel β 1  adrenoreceptor ligands that find use as imaging agents within nuclear medicine applications (e.g., PET imaging and SPECT imaging) are provided. Methods of imaging, including methods of imaging congestive heart failure, are also provided. The novel compounds may exhibit high affinity and selectivity, minimal metabolism, minimal non-specific binding and have a favorable log P value (&lt; 0). In some instances, β 1 -AR selective ligands are conjugated to an imaging moiety in such a way that it does not impact the antagonist affinity and their use. In other instances, the conjugation may be directly to the antagonist at several sites that will not impact affinity. In further instances, the conjugation may be by means of a linking group, which can be used to alter the pharmacokinetics and clearance of the complex.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a method and a device for determining a recommended value associated with the dosage of an active ingredient based on a series of measurement of at least one physiological parameter of patient.  &lt;P&gt;SOLUTION: The method includes the step of executing a series of measurement of at least one physiological parameter, specially a blood value, for example, blood sugar, in which samples S are sampled from a patient at discrete measurement times n and measurement is conducted to these samples. A recommended value DS associated with the dosage of active ingredient to be administered to a patient by the next measurement time is determined from the measurement, and in order to determine the value, dosage proposal algorithm incorporating at least one measured physiological parameter is applied. This enables adjusting at least one physiological parameter in a target range, or maintaining in the target range. For the dosage proposal algorithm, next measurement times (n+1), (n+1)&#39;, (n+1)&#34; are determined with consideration of a measurement exclusion time window (EX) and reported to a person in charge optionally.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
A dental preparation comprises a compound of formula &lt;FORM:0771768/VI/1&gt; where R represents an alkyl, hydroxy-tertiary butyl, butylamino-propyl or dicyclohexyl group and a compatible vehicle. The preparation may be in the form of a paste, powder or liquid dentifrice, mouthwash, chewing gum, tablet or troche.  R may be isopropyl, secondary butyl, ethylhexyl, dodecly, tetradecyl and hexadecyl groups.  A concentrate of the pyrimidine compound and a surface active agent (an ethanolamine salt or a sorbitan ether-ester) may be prepared and added to the vehicle. Water-soluble oxolates, e.g. sodium, potassium, ammonium or the urea salt, may also be present in addition to the conventional vehicle.  Example 1 describes a paste dentifrice comprising 1:3 - di - (ethyl hexyl) - 5 - methyl - 5 - amino - hexahydropyrimidine and a complex sorbitol ether-ester dispersing agent in a paste comprising calcium sulphate, calcium phosphate, sodium lauryl-sulphoacetate, gum tragacanth, sodium saccharin, glycerine, d  - sorbitol, flavouring and water.